The role of Immunotherapy by using NK cell therapy and Interleukin therapy in COVID-19
کد: G-08473
نویسندگان: Nastaran Nikkhou ©, Parvaneh Farzaneh
زمان بندی: زمان بندی نشده!
برچسب: ایمنی شناسی
دانلود: دانلود پوستر
خلاصه مقاله:
Background and Aim
Vaccination suitable solution for controlling the coronavirus disease (COVID-19) pandemic, but still there are some challenges in COVID-19 vaccination. Also, another medicinal option is Immunotherapy. Restoration of NK cell effector processes has the potential to correct the temperate immune balance required to effectively overcome SARS-CoV-2 infection. transfer of NK or CAR-NK cells with useful cytolytic potentials and the lowest capacity of cytokine-release to severe COVID-19 patients may provide an efficacious treatment mainly in cases suffering from cytokine storms.
Methods
Interleukins (ILs) 2, 12, 15, and 18 released by targets infected with the virus or active antigen-presenting cells can modulate NK cell function while increasing survival, proliferation, cytotoxicity, and cytokine production. IL-12 increases the production and secretion of IFN-γ by NK cells while IL-15 induces NK proliferation. Interleukin treatment can improve the effective function of NK cells. Given the importance of IL-15 signaling and NK cell function, researchers have created an "alternative" to IL-15, which is IL-15: IL-15R heterodimers that have better stability and bioactivity than IL-15 monomers. They have inside the body. Interleukin-6 (IL-6) is also a prognostic marker for COVID-19 infection, and tocilizumab blocks its receptors, the drug of choice for COVID-19 infection.
Results
the supplementation of IL-2 and IL-15 supplies more NK cell maturing (CD56dim phenotype) with an applicable cytolytic effect. with the technologies available to create chimeric antigen receptor (CAR)-NK cells, it is nowadays too possible to design specific cell lines expressing any receptor. However, because these interleukins also act as pro-inflammatory cytokines, their therapeutic use should be associated with severe alert to control the worsening of COVID-19 patient's inflammatory conditions because of expanded levels of IL-15 also chronic pulmonary inflammatory diseases, and Middle East respiratory syndrome coronavirus (MERS- CoV) infection.
Conclusion
Immunotherapy has a remarkable effect on reducing mortality and morbidity of patients with COVID-19. Given the significance of maintaining the innate immune system, particularly the function of NK cells to halt cytokine storms, be effective in preventing either acute diseases of COVID-19 or in the cure of severe conditions of this disease. appears that if the cytokine therapy is successful, their use in the cure of COVID-19 patients can be beneficial than NK cell therapies.
Keywords
Immunotherapy; NK cell therapy; Interleukin therapy; COVID-19; Vaccine
دیدگاه ها (0)
ارسال یک دیدگاه
ارسال دیدگاه توسط مدیریت بسته شده است.